Novartis 3Q Revenues: $13.8 billion (-7%) 3Q Earnings: $3.3 billion (-8%) YTD Revenues: $41.8 billion (-4%) YTD Earnings: $9.7 billion (-7%) Comments: Pharmaceutical sales were $7.8 billion in the quarter (-5%), in part due to the U.S. patent expiration of Diovan. Alcon net sales were $2.5 billion (-1%). Sandoz sales declined 13% to $2.0 billion. Vaccines and Diagnostics sales were down 11% to $582 million, driven by lower flu sales and shipment delays from one of the company’s manufacturi...